FI117556B - Rekombinant-DNA-förfarande för produktion av den glialderiverade neurotrofiska faktorn - Google Patents
Rekombinant-DNA-förfarande för produktion av den glialderiverade neurotrofiska faktorn Download PDFInfo
- Publication number
- FI117556B FI117556B FI941285A FI941285A FI117556B FI 117556 B FI117556 B FI 117556B FI 941285 A FI941285 A FI 941285A FI 941285 A FI941285 A FI 941285A FI 117556 B FI117556 B FI 117556B
- Authority
- FI
- Finland
- Prior art keywords
- gdnf
- acid sequence
- sequence
- nucleic acid
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Wood Science & Technology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
Claims (6)
1. Rekombinant DNA-förfarande för produktion av den glialderiverade neurotrofiskä faktorn (GDNF), kän-5 netecknat av att det omfattar stegen: (a) delkloning av en nukleinsyrasekvens, som kodar för den glialderiverade neurotrofiskä faktorn (GDNF), in i en expressionsvektor som innehäller de reglerande elemen-ten, vilka behövs för exprimering av den däri delklonade 10 nukleinsyrasekvensen, och väri nämnda nukleinsyrasekvens omfattar en nukleinsyrasekvens som har valts bland följan- ; de: i. en nukleinsyrasekvens, som kodar för en i figur 13 visad aminosyrasekvens (sekvens ID-nummer 3) av pre- 15. pro-rätt-GDNF; ii. en nukleinsyrasekvens, som kodar för en i fi- I gur 13 visad aminosyrasekvens (sekvens ID-nummer 4) av i fullvuxet rätt-GDNF; iii. en nukleinsyrasekvens, som kodar för en i fi- 20 gur 19 (sekvens ID-nummer 5) och 22 (sekvens ID-nummer 8) : visad aminosyrasekvens av human pre-pro-GDNF; • · · ’.'V iv. en nukleinsyrasekvens, som kodar för en i fi- • · · . rj \ *. gur 19 visad aminosyrasekvens (sekvens ID-nummer 6) av * * fullvuxet human GDNF; ·····' 25 v. en nukleinsyrasekvens, som kodar för en amino- • · * ·...* syrasekvens med en över 70-procentig homologigrad med • · · V * sekvenser visade med ID-nummer 4; vi. en nukleinsyrasekvens, som kodar för en amino- S Γ*ϊ syrasekvens med en över 70-procentig homologigrad med :***: 30 sekvenser visade med ID-nummer 6; * · · 1. vii. en nukleinsyrasekvens, som hybridiseras under • · · J stränga förhällanden med den komplementära sekvensen av . * · >' *·;·* den i punkt (i)-(vi) visade sekvensen *t**: (b) transformering av en värdcell med nämnda ex- ·*·.· 35 pressionsvektor; • · '4 ·. . I 117556 104 (c) odling av värdceller i förhällanden för förök- ning av vektorn och expression av den glialderiverade neu-rotrofiska faktorn (GDNF); och : (d) tillvaratagande av den glialderiverade neuro-5 trofiska faktorn (GDNF) frän värdcellodlingen.
2. Rekombinant-DNA-förfarande enligt patentkrav 1, kännetecknat av att det dessutom omfattar ett steg, där den tillvaratagna glialderiverade neurotrofiska fak- torn (GDNF) ätervikas och där den ätervikade GDNF har en 10 förmäga att främja upptagningen av dopamin i dopaminerga neuroner.
3. Rekombinant DNA-förfarande enligt patentkrav 1 eller 2, kännetecknat av att värdcellen är en animal cell. .,:,-
4. Rekombinant DNA-förfarande enligt patentkrav 3, kännetecknat av att värdcellen är en C0S-7-cell.
5. Rekombinant DNA-förfarande enligt patentkrav 1 eller 2, kännetecknat av att värdcellen är en bakte-riecell. ;
6. Rekombinant DNA-förfarande enligt patentkrav 5, kännetecknat av att värdcellen är coli. • · • · · • · · * · * · • « • · • · • · · • ·· • · · · · • * f # ··· • · · • * ® ' · · . .·. | • · · ? • · · • « · A • · • · ··· ··· • * * • * · • · • · • * • · · • · t Λ 1 *:»·; _ · '•f’it·
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76468591A | 1991-09-20 | 1991-09-20 | |
US76468591 | 1991-09-20 | ||
US77410991A | 1991-10-08 | 1991-10-08 | |
US77410991 | 1991-10-08 | ||
US78842391A | 1991-11-06 | 1991-11-06 | |
US78842391 | 1991-11-06 | ||
US85541392A | 1992-03-19 | 1992-03-19 | |
US85541392 | 1992-03-19 | ||
US9207888 | 1992-09-17 | ||
PCT/US1992/007888 WO1993006116A1 (en) | 1991-09-20 | 1992-09-17 | Glial derived neurotrophic factor |
Publications (3)
Publication Number | Publication Date |
---|---|
FI941285A FI941285A (sv) | 1994-03-18 |
FI941285A0 FI941285A0 (sv) | 1994-03-18 |
FI117556B true FI117556B (sv) | 2006-11-30 |
Family
ID=27505700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI941285A FI117556B (sv) | 1991-09-20 | 1994-03-18 | Rekombinant-DNA-förfarande för produktion av den glialderiverade neurotrofiska faktorn |
Country Status (21)
Country | Link |
---|---|
US (7) | US7226758B1 (sv) |
EP (2) | EP1243652A3 (sv) |
KR (1) | KR100242093B1 (sv) |
AT (1) | ATE275197T1 (sv) |
AU (2) | AU679167B2 (sv) |
CA (1) | CA2119463C (sv) |
DE (1) | DE69233407T2 (sv) |
DK (1) | DK0610254T3 (sv) |
ES (1) | ES2225819T3 (sv) |
FI (1) | FI117556B (sv) |
GE (1) | GEP20002243B (sv) |
HK (2) | HK1017816A1 (sv) |
HU (2) | HU220795B1 (sv) |
IL (5) | IL103223A (sv) |
MX (1) | MX9205293A (sv) |
NO (1) | NO321382B1 (sv) |
NZ (1) | NZ244392A (sv) |
PT (1) | PT100879B (sv) |
SG (1) | SG48145A1 (sv) |
TW (1) | TW401422B (sv) |
WO (1) | WO1993006116A1 (sv) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981165A (en) * | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | In vitro induction of dopaminergic cells |
WO1995006662A1 (en) * | 1993-09-01 | 1995-03-09 | Start Technology Partnership | Neuron regulatory factor for promoting neuron survival |
AU1443095A (en) * | 1993-12-22 | 1995-07-10 | University Of Medicine And Dentistry Of New Jersey | Novel nucleic acid sequences isolated from glial cells |
US6472585B1 (en) | 1994-04-25 | 2002-10-29 | Genentech, Inc. | Cardiotrophin-1 defective mouse |
US7258983B2 (en) | 1994-04-25 | 2007-08-21 | Genentech, Inc. | Cardiotrophin-1 compositions and methods for the treatment of tumor |
US5534615A (en) * | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
JP3906314B2 (ja) * | 1994-04-25 | 2007-04-18 | ジェネンテク・インコーポレイテッド | カルジオトロフィンおよびその使用 |
US5853385A (en) * | 1994-08-26 | 1998-12-29 | Cytotherapeutics, Inc. | Encapsulated PC12 cell transplants for treatment of Parkinson's disease |
US5733875A (en) * | 1994-11-15 | 1998-03-31 | Amgen Inc. | Methods of using GDNF as a neuroprotective agent |
JP3093974B2 (ja) * | 1995-06-27 | 2000-10-03 | 住友ベークライト株式会社 | 神経細胞用培養液、その製造方法及びこれを用いる神経細胞の培養方法 |
US6743628B1 (en) | 1995-08-28 | 2004-06-01 | Washington University | Method of cell culture using neurturin |
US5739307A (en) * | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
US5731284A (en) * | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
US6184200B1 (en) * | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
US5641749A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
US5641750A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
AU1121997A (en) * | 1995-11-29 | 1997-06-19 | Amgen, Inc. | Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product |
US5905027A (en) * | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
US5837681A (en) * | 1996-02-23 | 1998-11-17 | Amgen Inc. | Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5929041A (en) * | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
JP4301347B2 (ja) | 1996-03-14 | 2009-07-22 | ジェネンテク, インコーポレイテッド | Gdnfおよびgdnf受容体の用途 |
US6222022B1 (en) | 1996-03-14 | 2001-04-24 | Washington University | Persephin and related growth factors |
US6716600B1 (en) | 1996-03-14 | 2004-04-06 | Washington University | Persephin and related growth factors |
ES2237793T3 (es) | 1996-03-14 | 2005-08-01 | Washington University | Persefina y factores de crecimiento relacionados. |
US5741778A (en) * | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US6455277B1 (en) * | 1996-04-22 | 2002-09-24 | Amgen Inc. | Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides |
US7138251B1 (en) | 1996-04-22 | 2006-11-21 | Amgen Inc. | Polynucleotides encoding a neurotrophic factor receptor |
AU2677797A (en) * | 1996-04-25 | 1997-11-12 | Genetic Therapy, Inc. | Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor |
EP0922101B1 (en) * | 1996-07-29 | 2003-12-17 | BIOPHARM Gesellschaft zur biotechnologischen Entwicklung und zum Vertrieb von Pharmaka mbH | Egf-like factor from chromaffin granules and glia cell-derived neurotrophic factor with survival-promoting activity on daergic neurons |
ES2308800T3 (es) | 1997-01-08 | 2008-12-01 | Invitrogen Corporation | Metodos para la produccion de proteinas. |
US6777196B2 (en) | 1997-02-18 | 2004-08-17 | Genentech, Inc. | Neurturin receptor |
US6025157A (en) | 1997-02-18 | 2000-02-15 | Genentech, Inc. | Neurturin receptor |
US6372453B1 (en) | 1997-02-18 | 2002-04-16 | Genetech, Inc. | Neurturin receptor |
US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
EP1304119A3 (en) * | 1997-07-30 | 2004-01-21 | Amgen Inc. | Method for preventing and treating hearing loss using a neurturin protein product |
DE69837600T2 (de) * | 1997-08-05 | 2007-12-27 | F. Hoffmann-La Roche Ag | Aus einer menschlichen glial zelllinie-abgeleiteter promotor eines neurotrophischen faktors, diesen enthaltende vektoren und methoden zum screenen von verbindungen damit |
US7026138B1 (en) | 1998-03-23 | 2006-04-11 | Genentech, Inc. | Polynucleotides encoding GFRα3 |
AU765070B2 (en) | 1998-03-23 | 2003-09-11 | Genentech Inc. | GFRalpha3 and its uses |
DE19816186A1 (de) * | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-kodierende DNA, Teile davon und GDNF-Varianten |
US6593133B1 (en) | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
US6284540B1 (en) * | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
US7060676B2 (en) | 1999-12-20 | 2006-06-13 | Trustees Of Tufts College | T. cruzi-derived neurotrophic agents and methods of use therefor |
US20040014082A1 (en) * | 2000-08-11 | 2004-01-22 | Invitrogen Corporation | Highly homogeneous molecular markers for electrophoresis |
US6426065B1 (en) * | 2000-11-07 | 2002-07-30 | Clairol Incorporated | Use of tris(hydroxymethyl)aminomethane in cold permanent waving processes |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
AU2002250203B2 (en) | 2001-03-28 | 2006-08-10 | Biogen Ma Inc. | Use of neublastin polypeptides for treating neuropathic pain |
US20030050273A1 (en) * | 2001-08-29 | 2003-03-13 | Keiya Ozawa | Compositions and methods for treating neurodegenerative diseases |
US7613491B2 (en) * | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8364229B2 (en) * | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
JP2005526838A (ja) * | 2002-04-25 | 2005-09-08 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | パーキンソン病および他の神経変性疾患を治療するためのgdnf分泌ヒト神経幹細胞の使用 |
US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
US7528112B2 (en) | 2002-11-15 | 2009-05-05 | Drexel University | Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US20050048041A1 (en) * | 2003-01-13 | 2005-03-03 | Rao Mahendra S. | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
KR20060002745A (ko) * | 2003-01-13 | 2006-01-09 | 마헨드라 에스 라오 | 치료적 생성물의 전달을 위한 증식성 줄기세포 및전구세포에서의 후보 분자의 지속적 발현 |
US20040209810A1 (en) * | 2003-02-24 | 2004-10-21 | Gill Steven S. | Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor |
US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
CA2522364C (en) | 2003-04-18 | 2014-12-09 | Biogen Idec Ma Inc. | Polymer-conjugated glycosylated neublastin |
US7875293B2 (en) * | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
WO2004108760A2 (en) | 2003-06-10 | 2004-12-16 | Nsgene A/S | Improved secretion of neublastin |
JP4708342B2 (ja) * | 2003-07-25 | 2011-06-22 | デックスコム・インコーポレーテッド | 埋設可能な装置に用いる酸素増大膜システム |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
EP1662879A4 (en) * | 2003-08-29 | 2009-03-11 | Univ New York | INDIRECT ADMINISTRATION OF GROWTH FACTORS IN THE CENTRAL NERVOUS SYSTEM |
US20060258576A1 (en) * | 2003-09-05 | 2006-11-16 | Licentia, Ltd | Gdnf-related neuropeptides |
US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
US20060239966A1 (en) * | 2003-10-20 | 2006-10-26 | Tornoee Jens | In vivo gene therapy of parkinson's disease |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US20050123526A1 (en) * | 2003-12-01 | 2005-06-09 | Medtronic Inc. | Administration of growth factors for neurogenesis and gliagenesis |
US8093205B2 (en) * | 2003-12-01 | 2012-01-10 | Medtronic, Inc. | Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis |
WO2005079257A2 (en) * | 2004-02-12 | 2005-09-01 | Dexcom, Inc. | Biointerface with macro- and micro- architecture |
WO2009048462A1 (en) | 2007-10-09 | 2009-04-16 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
GB2414934A (en) * | 2004-06-11 | 2005-12-14 | Gill Steven Streatfield | Treatment of Parkinson's disease with GDNF |
CA2568150A1 (en) * | 2004-06-21 | 2006-01-05 | Medtronic, Inc. | Medical systems and methods for delivering compositions to cells |
US20060020192A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
CA2577690C (en) | 2004-08-19 | 2013-08-06 | Biogen Idec Ma Inc. | Refolding transforming growth factor beta family proteins |
SI1786454T1 (sl) | 2004-08-19 | 2010-10-29 | Biogen Idec Inc | Variante neoblastina |
US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
JP2009504689A (ja) * | 2005-08-16 | 2009-02-05 | ユニバーシティ オブ コペンハーゲン | Gdnf由来ペプチド |
US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
US8053569B2 (en) * | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
EP1940471A1 (en) * | 2005-10-28 | 2008-07-09 | NsGene A/S | IMPLANTABLE BIOCOMPATIBLE IMMtTNOISOLATORY VEHICLE FOR DELIVERY OF GDNF |
PL1969003T3 (pl) * | 2005-12-14 | 2011-05-31 | Herantis Pharma Plc | Zastosowanie białka czynnika neurotroficznego |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
WO2007120381A2 (en) * | 2006-04-14 | 2007-10-25 | Dexcom, Inc. | Analyte sensor |
DK2019683T4 (da) | 2006-04-25 | 2022-08-29 | Univ California | Indgivelse af vækstfaktorer til behandling af CNS-lidelser |
JP2009535360A (ja) * | 2006-04-26 | 2009-10-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 高分子量神経治療薬の対流増加送達のための組成物および方法 |
EP1872790A1 (en) | 2006-06-26 | 2008-01-02 | DeveloGen Aktiengesellschaft | New formulation for increasing bioavailability of neurturin |
US8759297B2 (en) * | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
KR100770440B1 (ko) * | 2006-08-29 | 2007-10-26 | 삼성전기주식회사 | 질화물 반도체 발광소자 |
US8637459B2 (en) * | 2006-11-08 | 2014-01-28 | Emory University | Enhancing a population of insulin releasing cells using GFR-A1 agonists |
CA2685686A1 (en) | 2007-05-01 | 2008-11-13 | Biogen Idec Ma Inc. | Neublastin polypeptides for use increasing vascularization in a tissue |
US20090011040A1 (en) * | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
US20200037875A1 (en) | 2007-05-18 | 2020-02-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
WO2008157308A2 (en) * | 2007-06-13 | 2008-12-24 | Wayne State University Board Of Governors | A zwitterion solution for low-volume therapeutic delivery |
EP2167071B1 (en) | 2007-06-13 | 2020-03-18 | Wayne State University Board Of Governors | A baclofen solution for low-volume therapeutic delivery |
EP2182980A4 (en) | 2007-07-27 | 2012-04-18 | Armagen Technologies Inc | METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS |
FI20070808A0 (sv) | 2007-10-25 | 2007-10-25 | Mart Saarma | Splitsvarienter av GDNF och användningar därav |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9839395B2 (en) | 2007-12-17 | 2017-12-12 | Dexcom, Inc. | Systems and methods for processing sensor data |
GB0803352D0 (en) * | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
US20090247856A1 (en) | 2008-03-28 | 2009-10-01 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
FI20080326A0 (sv) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotrofisk faktor MANF och dess användningar |
BRPI0912683A2 (pt) | 2008-05-15 | 2016-01-26 | Transmolecular Inc | tratamento de tumores metastáticos |
JP6066035B2 (ja) | 2009-02-12 | 2017-01-25 | クルナ・インコーポレーテッド | グリア細胞由来神経栄養因子(gdnf)関連疾病の、gdnfに対する天然アンチセンス転写物の抑制による治療 |
EP2408474B1 (en) | 2009-03-18 | 2019-06-26 | Armagen, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
WO2010144696A1 (en) | 2009-06-11 | 2010-12-16 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
EP3533467B1 (en) | 2009-10-09 | 2023-07-26 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
WO2011064437A2 (es) | 2009-11-26 | 2011-06-03 | Proyecto De Biomedicina Cima, S.L. | Vectores virales y procedimientos útiles en la preparación de gdnf |
EP2531206B1 (en) | 2010-02-04 | 2017-05-31 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
CN106957356B (zh) | 2010-05-11 | 2021-05-25 | 弗雷德哈钦森癌症研究中心 | 氯毒素变体、缀合物及其使用方法 |
CN103502464B (zh) | 2010-12-02 | 2016-03-23 | 神经技术美国有限公司 | 分泌抗血管生成抗体支架和可溶性受体的细胞系及其用途 |
UA112981C2 (uk) | 2011-04-11 | 2016-11-25 | Елі Ліллі Енд Компані | Варіант людського gdnf |
US9549692B2 (en) | 2011-08-26 | 2017-01-24 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
AU2012346448B2 (en) | 2011-12-02 | 2017-09-14 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
US9788765B2 (en) | 2012-09-28 | 2017-10-17 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
RU2015126650A (ru) | 2012-12-10 | 2017-01-12 | Фред Хатчинсон Кэнсер Рисёрч Сентер | Партнеры липокалина по слиянию |
WO2014152511A1 (en) | 2013-03-15 | 2014-09-25 | The Jackson Laboratory | Methods for promoting wound healing and hair growth |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
US10369329B2 (en) | 2014-01-30 | 2019-08-06 | Renishaw Plc | Neurosurgical apparatus and method |
EP3140429B1 (en) | 2014-05-05 | 2020-02-19 | Medtronic Inc. | Methods for scd, crt, crt-d, or sca therapy identification and/or selection |
US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
GB201506052D0 (en) | 2015-04-09 | 2015-05-27 | Renishaw Plc | Movement disorder |
CA2986769A1 (en) | 2015-05-27 | 2016-12-01 | Neurotech Usa, Inc. | Use of encapsulated cell therapy for treatment of ophthalmic disorders |
US20170188923A1 (en) | 2015-12-30 | 2017-07-06 | Dexcom, Inc. | Diffusion resistance layer for analyte sensors |
JP2019535267A (ja) | 2016-11-10 | 2019-12-12 | ケロス セラピューティクス インコーポレイテッドKeros Therapeutics,Inc. | Gdnf融合ポリペプチド及びその使用方法 |
AU2022238919A1 (en) | 2021-03-19 | 2023-10-19 | Dexcom, Inc. | Drug releasing membrane for analyte sensor |
WO2023043908A1 (en) | 2021-09-15 | 2023-03-23 | Dexcom, Inc. | Bioactive releasing membrane for analyte sensor |
CA3228457A1 (en) | 2022-02-02 | 2023-08-10 | Dexcom, Inc. | Sensing systems and methods for diagnosing, staging, treating, and assessing risks of liver disease using monitored analyte data |
WO2023164584A1 (en) | 2022-02-23 | 2023-08-31 | Dexcom, Inc. | Sensing systems and methods for providing decision support around kidney health and/or diabetes |
CA3238100A1 (en) | 2022-06-01 | 2023-12-07 | Dexcom, Inc. | Sensing systems and methods for diagnosing kidney disease |
WO2024050126A2 (en) | 2022-09-02 | 2024-03-07 | Dexcom, Inc. | Continuous analyte sensor devices and methods |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4518526A (en) * | 1982-12-22 | 1985-05-21 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
EP0154434B1 (en) | 1984-02-17 | 1993-01-27 | Genentech, Inc. | Human transforming growth factor and precursor or fragment thereof, cells, dna, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods |
US4886747A (en) | 1985-03-22 | 1989-12-12 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
US5284763A (en) | 1985-03-22 | 1994-02-08 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
US5089396A (en) | 1985-10-03 | 1992-02-18 | Genentech, Inc. | Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
US5427780A (en) | 1985-10-30 | 1995-06-27 | Biogen, Inc. | Composition comprising Mullerian inhibiting substance-like polypeptides |
EP0233838A3 (en) | 1986-02-04 | 1990-01-31 | Incyte Pharmaceuticals, Inc. | Neurite-promoting factor and process for the manufacture thereof |
US5187076A (en) * | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5324819A (en) | 1988-04-08 | 1994-06-28 | Stryker Corporation | Osteogenic proteins |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US5250414A (en) | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
WO1990005191A1 (en) * | 1988-11-04 | 1990-05-17 | Erziehungsdirektion Of The Canton Zurich | Neurite growth regulatory factors |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5017735A (en) | 1989-07-24 | 1991-05-21 | Catalytica, Inc. | Selective sorption of 2,6-diisopropylnaphthalene |
AU6174490A (en) | 1989-08-04 | 1991-03-11 | Board Of Regents, The University Of Texas System | Methods and compositions; purified preparation of neural progenitor regulatory factor |
US5215969A (en) | 1989-08-11 | 1993-06-01 | Hahnemann University | Dopaminergic neurotrophic factor for treatment of Parkinson's disease |
EP0486584A4 (en) * | 1989-08-11 | 1993-02-03 | Hahnemann University | Dopaminergic neurotrophic factor for treatment of parkinson's disease |
WO1991010470A1 (en) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Devices and methods for enhanced delivery of active factors |
US5270181A (en) | 1991-02-06 | 1993-12-14 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
-
1992
- 1992-09-17 CA CA002119463A patent/CA2119463C/en not_active Expired - Lifetime
- 1992-09-17 AU AU26811/92A patent/AU679167B2/en not_active Expired
- 1992-09-17 GE GEAP19922636A patent/GEP20002243B/en unknown
- 1992-09-17 US US08/182,183 patent/US7226758B1/en not_active Expired - Lifetime
- 1992-09-17 KR KR1019940700860A patent/KR100242093B1/ko not_active IP Right Cessation
- 1992-09-17 DK DK92921022T patent/DK0610254T3/da active
- 1992-09-17 DE DE69233407T patent/DE69233407T2/de not_active Expired - Lifetime
- 1992-09-17 EP EP02009293A patent/EP1243652A3/en not_active Withdrawn
- 1992-09-17 AT AT92921022T patent/ATE275197T1/de active
- 1992-09-17 SG SG1996007336A patent/SG48145A1/en unknown
- 1992-09-17 WO PCT/US1992/007888 patent/WO1993006116A1/en active IP Right Grant
- 1992-09-17 EP EP92921022A patent/EP0610254B1/en not_active Expired - Lifetime
- 1992-09-17 HU HU9400717A patent/HU220795B1/hu unknown
- 1992-09-17 ES ES92921022T patent/ES2225819T3/es not_active Expired - Lifetime
- 1992-09-17 MX MX9205293A patent/MX9205293A/es unknown
- 1992-09-18 IL IL10322392A patent/IL103223A/xx not_active IP Right Cessation
- 1992-09-18 PT PT100879A patent/PT100879B/pt not_active IP Right Cessation
- 1992-09-18 NZ NZ244392A patent/NZ244392A/en not_active IP Right Cessation
- 1992-10-23 TW TW081108487A patent/TW401422B/zh not_active IP Right Cessation
-
1994
- 1994-03-15 NO NO19940922A patent/NO321382B1/no not_active IP Right Cessation
- 1994-03-18 FI FI941285A patent/FI117556B/sv not_active IP Right Cessation
-
1995
- 1995-05-26 US US08/452,242 patent/US5935795A/en not_active Expired - Lifetime
- 1995-05-26 US US08/452,229 patent/US6362319B1/en not_active Expired - Lifetime
- 1995-05-26 US US08/451,374 patent/US6093802A/en not_active Expired - Lifetime
- 1995-05-30 US US08/453,176 patent/US6015572A/en not_active Expired - Lifetime
- 1995-06-28 HU HU95P/P00478P patent/HU211984A9/hu unknown
-
1997
- 1997-04-21 AU AU19001/97A patent/AU694387B2/en not_active Expired
- 1997-09-22 US US08/935,268 patent/US6221376B1/en not_active Expired - Fee Related
- 1997-10-07 IL IL12191397A patent/IL121913A0/xx unknown
-
1998
- 1998-12-28 HK HK98117977A patent/HK1017816A1/xx not_active IP Right Cessation
-
2000
- 2000-12-31 IL IL14065300A patent/IL140653A0/xx unknown
- 2000-12-31 IL IL14065400A patent/IL140654A0/xx unknown
-
2001
- 2001-11-13 US US09/991,119 patent/US20020197675A1/en not_active Abandoned
-
2002
- 2002-01-06 IL IL14748802A patent/IL147488A0/xx unknown
- 2002-12-03 HK HK02108799.4A patent/HK1047438A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI117556B (sv) | Rekombinant-DNA-förfarande för produktion av den glialderiverade neurotrofiska faktorn | |
AU664975B2 (en) | Chimeric neurotrophic factors | |
FI105342B (sv) | Förfarande för framställning av ett protein som har aktiviteten av en hjärnderiverad neurotrofisk faktor (BDNF) | |
ES2314999T3 (es) | Factor celular madre. | |
FI105343B (sv) | Nukleinsyrasekvens som kodar neurotrofin-3 (NT-3) -protein och använding av denna | |
PT101297B (pt) | Polipeptideos que sao factores de crescimento mitogenicos para celulas da glia, sequencias de dna que os codificam e aplicacao terapeutica destes polipeptideos | |
CA2137799A1 (en) | Therapeutic and diagnostic methods based on neurotrophin-4 expression | |
JP2968840B2 (ja) | グリア由来神経栄養因子 | |
US20040175795A1 (en) | Glial derived neurotrophic factor | |
CA2202496C (en) | Neurotrophic peptides of activity dependent neurotrophic factor | |
DD298133A5 (de) | Ziliarer neurotroper faktor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or assigment of application |
Owner name: AMGEN INC. |
|
FG | Patent granted |
Ref document number: 117556 Country of ref document: FI |
|
MA | Patent expired |